Management of Anemia and Iron Deficiency in Heart Failure
- 197 Downloads
Anemia is independently associated with an increased risk of mortality and morbidity in patients with heart failure (HF). The diagnosis of anemia should prompt assessment of the underlying cause(s), first by using routine laboratory measurements (i.e., serum creatinine and estimated glomerular filtration rate [eGFR], serum iron, transferrin saturation, ferritin, vitamin B12, folic acid, and thyroid stimulating hormone). In clinical practice, it remains unclear whether using levels of the soluble transferrin receptor in HF patients to assess iron deficiency is warranted. Further investigation should follow these simple tests when judged appropriate (e.g., if occult gastrointestinal blood losses are suspected). Hemodilution may contribute significantly to anemia in patients with advanced HF and may be suspected when signs of hypervolemia are present. Euvolemia should be the first goal in such cases (as always), followed by optimization of the disease-modifying therapies used in HF (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, β-blockers, or aldosterone antagonists and cardiac resynchronization therapy in selected cases). Erythropoiesis-stimulating agents (ESA) can be used to improve functional capacity in patients with significant chronic kidney disease (CKD), a frequent comorbidity in HF patients. ESA and iron therapy is recommended in patients with moderate-to-severe CKD (eGFR < 60 mL/min/1.73 m2), with a target hemoglobin level of 11.0 g/dL. In a recent randomized, placebo-controlled clinical trial, weekly administration of intravenous iron significantly improved symptoms, New York Heart Association class, quality of life, and exercise capacity in both anemic and non-anemic HF patients. A trend toward fewer hospitalizations was seen in the group treated with intravenous iron. The rates of adverse events were similar in the treatment and the placebo groups. Larger-scale and longer-term studies are needed to establish the safety and efficacy profile of intravenous iron in non-CKD HF patients and in HF patients without anemia. Studies designed to further unravel the pathophysiology of anemia in HF are essential in order to determine 1) novel treatment targets and 2) whether and how the treatment of anemia could improve outcomes.
Eileen O’Meara’s clinical research on heart failure has been supported by Les Fonds de Recherche en Santé du Québec (FRSQ) and grants from Johnson & Johnson and Pfizer.
Simon de Denus is supported by the Heart and Stroke Foundation of Canada and Les Fonds de la recherche en santé du Québec (FRSQ), and has received grants from AstraZaneca, Pfizer, and Hoffmann LaRoche.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 9.O’Meara E, Clayton T, McEntegart MB, et al.: Clinical correlates and consequence of anemia in a broad spectrum of patients with heart failure—results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) Program. Circulation 2006, 113:986–994.CrossRefPubMedGoogle Scholar
- 58.Desai A, Lewis E, Solomon S, et al.: Impact of erythropoiesis-stimulating agents on morbidity and mortality in patients with heart failure: an updated, post-TREAT meta-analysis. Eur J Heart Fail 2010 Jun 5 [Epub ahead of print].Google Scholar
- 60.•Anker SD, Colet JC, Filippatos G, on behalf of the FAIR-HF Committees Investigators, et al.: Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail 2009, 11:1084–1091. This is an interesting article explaining the role of iron and the potential benefits that could be gained from iron therapy in HF. It also includes a review of the previous trials of intravenous iron therapy in HF patients.CrossRefPubMedGoogle Scholar
- 64.Okonko DO, Grzeslo A, Witkowski T, et al.: Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008, 51:103–112.CrossRefPubMedGoogle Scholar
- 67.National Kidney Foundation Kidney Disease Outcomes Quality Initiative: KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target; 2007. Available at http://www.kidney.org/professionals/KDOQI/. Accessed July 14, 2010.
- 68.Hunt SA, Abraham WT, Chin MH, et al.: 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119:e391–479.CrossRefPubMedGoogle Scholar
- 69.••Locatelli F, Aljama P, Canaud B, et al., on behalf of the Anaemia Working Group of European Renal Best Practice (ERBP): Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp(R) Therapy (TREAT) Study. Nephrol Dial Transplant 2010 Jun 29 [Epub ahead of print]. This is an important guideline reference (from a different group) for clinicians who prescribe ESAs in patients with CKD. The reference was written after publication of TREAT.Google Scholar